Clinical Trial

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-26; most recent amendment 2025-08-12.
Trial Details
NCT Number NCT06907615
Lead Sponsor Shanghai Henlius Biotech
Collaborators: Henlius USA Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 243 participants
Start Date 2025-06-09
Primary Completion 2028-04-20 (estimated)
Study Completion 2028-06-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-17